Small molecule compounds and monoclonal antibody therapy in lung cancer

Silin Liu

doi:10.54254/2753-8818/2024.18017

Research Article

Open access

Published on 6 December 2024

Download pdf

Liu,S. (2024). Small molecule compounds and monoclonal antibody therapy in lung cancer. Theoretical and Natural Science,67,7-11.

Export citation

Small molecule compounds and monoclonal antibody therapy in lung cancer

Silin Liu *^,1,

¹ Beijing Lu He International Academy, Beijing,10010 China

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/2024.18017

Abstract

The leading cause of cancer-related mortality worldwide is lung cancer, with ongoing challenges in treatment efficacy and safety, but recent advances have been made in targeted therapies, including small molecule inhibitors and monoclonal antibodies, have significantly improved treatment precision and reduced side effects compared to traditional methods. Despite these developments, gaps remain in fully understanding resistance mechanisms and identifying novel therapeutic targets. This paper reviews the current state of targeted therapies for lung cancer, examining their mechanisms, clinical applications, and impact on patient outcomes. It provides valuable insights into how these therapies have advanced the field and highlights areas where further research is needed. Future studies should focus on addressing these gaps and exploring new approaches to optimize treatment and enhance patient survival rates.

Keywords

Lung cancer, risk factors, immunotherapy

View pdf

References

[1]. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.

[2]. Finley, R. S. (2003). Overview of targeted therapies for cancer. American Journal of Health-System Pharmacy, 60(suppl_9), S4-S10.

[3]. Adams, G. P., & Weiner, L. M. (2005). Monoclonal antibody therapy of cancer. Nature Biotechnology, 23(9), 1147-1157.

[4]. Martens, U. M. (Ed.). (2018). Small molecules in oncology (Vol. 211). Springer.

[5]. DeutscheKrebsgesellschaft. (2001). Journal of Cancer Research and Clinical Oncology. Springer-Verlag.

[6]. Herrera-Juárez, M., Serrano-Gómez, C., Bote-de-Cabo, H., & Paz-Ares, L. (2023). Targeted therapy for LC: Beyond EGFR and ALK. Cancer, 129(12), 1803-1820.

[7]. Harrison, P. T., Vyse, S., & Huang, P. H. (2020). Rare epidermal growth factor receptor (EGFR) mutations in non-small cell LC. Seminars in Cancer Biology, 61, 167-179.

[8]. Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023). ALK-positive LC: A moving target. Nature Cancer, 4(3), 330-343.

[9]. Spagnolo, C. C., Ciappina, G., Giovannetti, E., et al. (2023). Targeting MET in non-small cell LC (NSCLC): A new old story? International Journal of Molecular Sciences, 24(12), 10119.

[10]. Bade, B. C., & Dela Cruz, C. S. (2020). LC 2020: Epidemiology, etiology, and prevention. Clinical Chest Medicine, 41(1), 1-24.

[11]. Chest Medicine, 41(1), 1-24. Travis, M. J., et al. (2013). Long-term risk of LC after radiation therapy for breast cancer. Journal of Clinical Oncology, 31(18), 2260-2267.

[12]. Chen, E. C. K., et al. (2009). Socioeconomic status and cancer incidence: A meta-analysis. Cancer Epidemiology, Biomarkers & Prevention, 18(1), 37-51.

Cite this article

Liu,S. (2024). Small molecule compounds and monoclonal antibody therapy in lung cancer. Theoretical and Natural Science,67,7-11.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science

Conference website: https://2024.icbiomed.org/

ISBN：978-1-83558-765-2(Print) / 978-1-83558-766-9(Online)

Conference date: 25 October 2024

Editor：Alan Wang

Series: Theoretical and Natural Science

Volume number: Vol.67

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).